SCHEMBL4530260

SCHEMBL4530260

CCCCC(CCc1cccc2c1CCc1sc(NC(=O)c3cc(F)c(/C=C(\C)C(=O)O)c(F)c3)nc1-2)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 5/20 0.41
ABCB11 O95342 1/20 0.40
F2 P00734 1/20 0.40
ESR1 P03372 1/20 0.40
PGR P06401 1/20 0.40
HTR1A P08908 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD1 P21728 1/20 0.40
TBXA2R P21731 1/20 0.40
PTGS1 P23219 1/20 0.40
PDE4A P27815 1/20 0.40
ADRA1A P35348 1/20 0.40
DRD3 P35462 1/20 0.40
KCNH2 Q12809 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
MAPT P10636 11/20 0.39
TP53 P04637 6/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530264 1.00 MPL (0.41) MPLABCB11F2ESR1PGR
SCHEMBL4499887 0.96 MAPT (0.40) MPLABCB11F2ESR1PGR
SCHEMBL4499890 0.96 MAPT (0.40) MPLABCB11F2ESR1PGR
SCHEMBL4524827 0.95 MAPT (0.41) MPLABCB11F2ESR1PGR
SCHEMBL4524822 0.95 MAPT (0.41) MPLABCB11F2ESR1PGR
SCHEMBL4527324 0.94 MPL (0.39) MPLABCB11F2ESR1PGR
SCHEMBL4527327 0.94 MPL (0.39) MPLABCB11F2ESR1PGR
SCHEMBL4521032 0.92 MPL (0.50) MPLABCB11F2ESR1PGR
SCHEMBL4521023 0.92 MPL (0.50) MPLABCB11F2ESR1PGR
SCHEMBL4513413 0.90 MAPT (0.38) MPLABCB11F2ESR1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655291-B1 COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO (JP) 2016-08-03 EP disclosed
US-20090318513-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. 2009-12-24 US disclosed
US-7601746-B2 Compounds exhibiting thrombopoietin receptor agonism SHIONOGI & CO., LTD. (JP) 2009-10-13 US disclosed
US-20070043087-A1 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2007-02-22 US disclosed
EP-1655291-A1 COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2006-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318513-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM MPL, TEK, GHRHR MPL 1/4885ABCB11 3063/4885F2 247/4885
US-20070043087-A1 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid DHFR, NAT1, ACR MPL 3714/4885ABCB11 41/4885F2 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.